Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

Published Date >> December 2011
No. Of Pages >> NA  

Single User License
$3500
      
Multi User License
$10500
Description

 

GBI Research, the leading business intelligence provider, has released its latest research “Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules”, which provides insights into global antipsychotic market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the antipsychotics market for bipolar disorder and schizophrenia. The report also provides the share of generics in global antipsychotic market as well as in each indication market. The report examines the global bipolar disorder and schizophrenia treatment usage patterns. In addition, geographical distribution of antipsychotic market across the US, the top five countries of Europe and in Japan. The report also includes insights into the antipsychotics R&D product pipeline and explores the competitive landscape including major players in antipsychotics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in antipsychotics market.

Scope

  • Data and analysis on the antipsychotic market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the antipsychotics market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Share of the generics in global antipsychotics market and for the market of each indication that is covered in the report.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global antipsychotic market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, Astra Zeneca, Bristol-Myers Squibb and Johnson & Johnson.
  • Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the antipsychotics market.

Reasons to Buy

  • Align your product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table of Contents

1.1 List of Tables 
1.2 List of Figures 

2 Antipsychotics Market to 2017 - Introduction
2.1 GBI Report Guidance 

3 Antipsychotics Market to 2017 - Global Market Overview
3.1 Introduction 
3.2 Revenue Forecasts 
3.2.1 Generic Share 
3.3 Annual Cost of Treatment 
3.4 Top Antipsychotics Drug Products 
3.4.1 Seroquel (quetiapine) 
3.4.2 Zyprexa (olanzapine) 
3.4.3 Abilify (aripiprazole) 
3.4.4 Risperdal (risperidone) 
3.4.5 Geodon (ziprasidone) 
3.5 Newer Antipsychotics 
3.5.1 Fanapt (iloperidone) 
3.5.2 Saphris / Sycrest (asenapine) 
3.5.3 Invega Sustenna (paliperidone palmitate extended release injectable suspension) 
3.5.4 Latuda (lurasidone Hcl) 

4 Antipsychotics Market to 2017 - Geographical Landscape
4.1 Revenue Analysis by Geography 
4.2 The US 
4.2.1 Revenue 
4.2.2 Annual Cost of Treatment 
4.3 Top Five Countries of Europe 
4.3.1 Revenue 
4.3.2 Annual Cost of Treatment 
4.4 Japan - Antipsychotics Market 
4.4.1 Revenue 
4.4.2 Annual Cost of Treatment 

5 Antipsychotics Market to 2017 - Therapeutic Landscape
5.1 Bipolar Disorder - Antipsychotics Market 
5.1.1 Introduction 
5.1.2 Revenue 
5.1.3 Annual Cost of Treatment 
5.1.4 Treatment Usage Patterns 
5.2 Drivers and Barriers to the Antipsychotics Market for Bipolar Disorder 
5.2.1 Drivers for Bipolar Disorder Therapeutics Market 
5.2.2 Barriers for Bipolar Disorder Therapeutics Market 
5.3 Schizophrenia - Antipsychotics Market 
5.3.1 Introduction 
5.3.2 Revenue 
5.3.3 Annual Cost of Treatment 
5.3.4 Treatment Usage Patterns 
5.4 Drivers and Barriers to the Antipsychotics Market for Schizophrenia 
5.4.1 Drivers for the Schizophrenia Therapeutics Market 
5.4.2 Barriers for the Schizophrenia Therapeutics Market 

6 Antipsychotics Market to 2017 - Product Pipeline Analysis
6.1 Introduction 
6.1.1 Antipsychotics Market to 2017- Discovery Stage Molecules 
6.1.2 Antipsychotics Market to 2017- Pre-clinical Stage Molecules 
6.1.3 Antipsychotics Market to 2017- Phase I Stage Molecules 
6.1.4 Antipsychotics Market to 2017- Phase II Stage Molecules 
6.1.5 Antipsychotics Market to 2017- Phase III Stage Molecules 
6.1.6 Antipsychotics Market to 2017- NDA Filed Molecules 
6.1.7 NDA filed molecules 

7 Antipsychotics Market to 2017 - Competitive Landscape
7.1 Market Share Analysis 
7.1.1 AstraZeneca 
7.1.2 Eli Lilly 
7.1.3 Bristol-Myers Squibb (BMS) 
7.1.4 Johnson & Johnson (J&J) 
7.1.5 Pfizer 

8 Antipsychotics Market to 2017 - M&A Landscape
8.1 M&A Deals (2007-2011) 
8.1.1 M&A Deals by Region 
8.1.2 M&A Deals by Value 
8.1.3 M&A Deals by Year 
8.1.4 Summary of M&A Deals (2009-2011) 
8.2 Licensing Deals 
8.2.1 Licensing Deals by Region 
8.2.2 Licensing Deals by Year 
8.2.3 Deal Summary (2010-2011) 
8.3 Co-development Deals 
8.3.1 Co-development Deals by Region 
8.3.2 Co-development Deals by Year 
8.3.3 Deal Summary (2010 - 2011) 

9 Antipsychotics Market to 2017 - Appendix
9.1 Market Definitions 
9.2 Abbreviations 
9.3 Research Methodology 
9.3.1 Coverage 
9.3.2 Secondary Research 
9.3.3 Primary Research 
9.3.4 Therapeutic Landscape 
9.3.5 Geographical Landscape 
9.3.6 Pipeline Analysis 
9.3.7 Competitive Landscape 
9.3.8 Expert Panel Validation 
9.4 Contact Us 
9.5 Disclaimer 
9.6 Sources

List of Table:


Table 1: Antipsychotics Market, Global, Revenue, ($m), 2002-2010 
Table 2: Antipsychotics Market, Global, Revenue Forecast, ($m), 2010-2017 
Table 3: Antipsychotics Market, Global, Annual Cost of Treatment ($), 2002-2010 
Table 4: Antipsychotics Market, Global, Annual Cost of Treatment ($), 2010-2017 
Table 5: Antipsychotics Market, Revenue of Leading Antipsychotics,($m),2008-2010 
Table 6: Antipsychotics Market, Newer Antipsychotics, 2009-2010 
Table 7: Antipsychotics Market, The US, Revenue ($m), 2002-2010 
Table 8: Antipsychotics Market, The US, Revenue Forecast ($m), 2010-2017 
Table 9: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2002-2010 
Table 10: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2010-2017 
Table 11: Antipsychotics Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 
Table 12: Antipsychotics Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2017 
Table 13: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 
Table 14: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 
Table 15: Antipsychotics Market, Japan, Revenue ($m), 2002-2010 
Table 16: Antipsychotics Market, Japan, Revenue Forecast ($m), 2010-2017 
Table 17: Antipsychotics Market, Japan, Annual Cost of Treatment ($), 2002-2010 
Table 18: Antipsychotics Market, Japan, Annual Cost of Treatment, ($), 2010-2017 
Table 19: Antipsychotics Market, Bipolar Disorder, Global, Revenue ($m), 2002-2010 
Table 20: Antipsychotics Market, Bipolar Disorder, Global, Revenue Forecast ($m), 2010-2017 
Table 21: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2002-2010 
Table 22: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2010-2017 
Table 23: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2010 
Table 24: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2010-2017 
Table 25: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2002-2010 
Table 26: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2010-2017 
Table 27: Antipsychotics Market, Schizophrenia, Global, Revenue ($m), 2002-2010 
Table 28: Antipsychotics Market, Schizophrenia, Global, Revenue Forecast ($m), 2010-2017 
Table 29: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2002-2010 
Table 30: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2010-2017 
Table 31: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010 
Table 32: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2010-2017 
Table 33: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2002-2010 
Table 34: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2010-2017 
Table 35: Antipsychotics Market, Discovery Stage Molecules, 2011 
Table 36: Antipsychotics Market, Preclinical Stage Molecules, 2011 
Table 37: Antipsychotics Market, Phase I Stage Molecules, 2011 
Table 38: Antipsychotics Market, Phase II Stage Molecules, 2011 
Table 39: Antipsychotics Market, Phase III Stage Molecules, 2011 
Table 40: Antipsychotics Market, NDA Filed Molecules, 2011 
Table 41: Antipsychotics Market, Global, M&A Deals, 2007-2011 
Table 42: Antipsychotics Market, Global, Licensing Deals, 2007-2011 
Table 43: Antipsychotics Market, Global, Co-developments Deals, 2008-2011 

List of Charts:


Figure 1: Antipsychotics Market, Global, Revenue Forecast, ($m), 2002-2017 
Figure 2: Antipsychotics Market, Global, Generic Share, (%), 2010 and 2017 
Figure 3: Antipsychotics Market, Global Annual Cost of Treatment ($), 2002-2017 
Figure 4: Antipsychotics Market, Revenue of Leading Antipsychotics,($m),2008-2010 
Figure 5: Antipsychotics Market, Revenue Analysis by Geography, (%), 2010 
Figure 6: Antipsychotics Market, The US, Revenue Forecast, ($m), 2002-2017 
Figure 7: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2002-2017 
Figure 8: Antipsychotics Market, Top Five Countries of Europe, Revenue Forecast ($m), 2002-2017 
Figure 9: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 
Figure 10: Antipsychotics Market, Japan, Revenue Forecast ($m), 2002-2017 
Figure 11: Antipsychotics Market, Japan, Annual Cost of Treatment ($), 2002-2017 
Figure 12: Antipsychotics Market, Bipolar Disorder, Treatment Algorithm, 2011 
Figure 13: Antipsychotics Market, Bipolar Disorder, Global, Revenue Forecast ($m), 2002-2017 
Figure 14: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2002-2017 
Figure 15: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2017 
Figure 16: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2002-2017 
Figure 17: Antipsychotics Market, Bipolar Disorder, Global Market Drivers and Barriers, 2010-2017 
Figure 18: Antipsychotics Market, Schizophrenia, Treatment Algorithm, 2011 
Figure 19: Antipsychotics Market, Schizophrenia, Global, Revenue Forecast ($m), 2002-2017 
Figure 20: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2002-2017 
Figure 21: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2017 
Figure 22: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2002-2017 
Figure 23: Antipsychotics Market, Schizophrenia, Global Market Drivers and Barriers, 2010-2017 
Figure 24: Antipsychotics Market, Product Pipeline Molecules by Clinical Stages of Development, (%), 2011 
Figure 25: Antipsychotics Market, Product Pipeline Molecules by Indication, (%), 2011 
Figure 26: Antipsychotics Market, Global Market Share Analysis,(%),2011 
Figure 27: Antipsychotics Market, SWOT Analysis of AstraZeneca, 2010 
Figure 28: Antipsychotics Market, SWOT Analysis of Eli Lilly, 2010 
Figure 29: Antipsychotics Market, SWOT Analysis of Bristol-Myers Squibb, 2010 
Figure 30: Antipsychotics Market, SWOT Analysis of Johnson & Johnson, 2010 
Figure 31: Antipsychotics Market, SWOT Analysis of Pfizer, 2010 
Figure 32: Antipsychotics Market, Global, Strategic Consolidation, 2007-2011 
Figure 33: Antipsychotics Market, Global, M&A Deals by Region, 2007-2011 
Figure 34: Antipsychotics Market, Global, M&A Deals by Value ($m), 2007-2011 
Figure 35: Antipsychotics Market, Global, M&A Deals by Year, 2007-2011 
Figure 36: Antipsychotics Market, Global, Licensing Deals by Region, 2007-2011 
Figure 37: Antipsychotics Market, Global, Licensing Deals by Year, 2007-2011 
Figure 38: Antipsychotics Market, Global Co-development Deals by Region, 2008-2011 
Figure 39: Antipsychotics Market, Global, Co-development Deals by Year, 2008-2011 
Figure 40: GBI Research Market Forecasting Model 

More Reports in Pharmaceutical

EGIS Pharmaceuticals Plc: Pharmaceuticals and Healthcare Company Profile & SWOT Report


Blue Cross Blue Shield of Michigan: Pharmaceuticals and Healthcare Company Profile & SWOT Report


Purdue Pharma L.P.: Pharmaceuticals and Healthcare Company Profile & SWOT Report


Mitsubishi Tanabe Pharma Corporation: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Nissan Chemical Industries, Ltd.: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Eisai Co., Ltd.: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Asahi Kasei Corporation: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Perrigo Company: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Align Technology, Inc.: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Daiichi Sankyo Company, Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report





By This Publisher

Natural Gas Industry to 2017 - Depleting Conventional Crude Oil Reserves and Emerging Technologies in Gas Consumption Infrastructure Driving Growth


Crude Oil Industry to 2016 - Deepwater Discoveries Worldwide and Rising Industrial Demand in Emerging Economies Driving the Industry


Iron Ore Mining Market in Asia-Pacific to 2020 - Interplay Between Regional Demand for Steel and Iron Production Shapes the Competitive Landscape


Iron Ore Mining Market in North America to 2020 - Demand for Steel in the US to Boost Regional Iron Ore Production


Power Market in SAARC Countries to 2020 - FDI Driven by Private Sector Participation is Key to Future Growth


Oil and Gas Enhanced Production Services Industry to 2016 - Enhanced Oil Recovery (EOR) Driving E&P Activity in Depleting Hydrocarbon Reservoirs


Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments


Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules


Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion


Regulatory Intelligence on Medical Device Recalls - Ineffective Process Control, Defects in Design of Device, Software or Other Components are the Major Reasons for Recall



Other Details :

Publisher : GBI Research

Report Category : Pharmaceutical

Formats of Delivery :  E-mail Delivery (PDF)

Similar Industry Reports :

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules